Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655850 | 1.00 | EPHX2 (0.56) | EPHX2NPC1RAB9ACCNCCDK8 | |
| SCHEMBL22686123 | 0.91 | EPHX2 (0.50) | EPHX2NPC1RAB9AABL1 | |
| SCHEMBL29655868 | 0.91 | EPHX2 (0.50) | EPHX2NPC1RAB9AABL1 | |
| SCHEMBL22685998 | 0.89 | EPHX2 (0.56) | EPHX2NPC1RAB9ACCNCCDK8 | |
| SCHEMBL22687397 | 0.86 | EPHX2 (0.53) | EPHX2NPC1RAB9ACCNCCDK8 | |
| SCHEMBL22685981 | 0.84 | EPHX2 (0.59) | EPHX2NPC1RAB9ACCNCCDK8 | |
| SCHEMBL23111679 | 0.84 | EPHX2 (0.51) | EPHX2NPC1RAB9A | |
| SCHEMBL22687455 | 0.83 | EPHX2 (0.50) | EPHX2NPC1RAB9A | |
| SCHEMBL22686013 | 0.83 | EPHX2 (0.57) | EPHX2NPC1RAB9ACCNCCDK8 | |
| SCHEMBL30645243 | 0.83 | EPHX2 (0.49) | EPHX2NPC1RAB9ACCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3968994-B1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-20220213074-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| WO-2020232153-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213074-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | ABHD12, SAMHD1, ABHD11 | EPHX2 460/4885NPC1 1734/4885RAB9A 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.